Table 1 Patient and tumor characteristics (N = 57)
Characteristic | Overall (n = 57) | Pre-neoadjuvant | p | Post-neoadjuvant | p | ΔSMI (%)/250 days | p | |||
|---|---|---|---|---|---|---|---|---|---|---|
Sarcopenia (n = 20) | No-sarcopenia (n = 37) | Sarcopenia (n = 30) | No-sarcopenia (n = 27) | SML (n = 25) | No-SML (n = 32) | |||||
Age (years), mean ± SD | 57.4 ± 10.7 | 56.0 ± 11.5 | 58.1 ± 10.4 | 0.723 | 57.6 ± 11.3 | 57.1 ± 10.2 | 0.885 | 57.9 ± 10.0 | 56.9 ± 11.4 | 0.735 |
ECOG, n (%) | ||||||||||
0 | 49 (86.00%) | 15 (75.00%) | 34 (91.89%) | 0.080 | 24 (80.00%) | 25 (92.59%) | 0.172 | 17 (68.00%) | 32 (100.00%) | 0.002 |
1 | 8 (14.00%) | 5 (15.00%) | 3 (8.11%) | 6 (20.00%) | 2 (7.41%) | 8 (32.00%) | 0 (0) | |||
BMI (Kg/m2), mean ± SD | ||||||||||
Pre-neoadjuvant | 22.82 ± 3.45 | 21.87 ± 3.32 | 23.33 ± 3.45 | 0.128 | 22.72 ± 3.67 | 22.93 ± 3.25 | 0.827 | 22.00 ± 3.26 | 23.46 ± 3.51 | 0.112 |
Post-neoadjuvant | 22.02 ± 3.49 | 20.40 ± 3.40 | 22.85 ± 3.54 | 0.338 | 21.80 ± 3.28 | 22.21 ± 3.71 | 0.665 | 20.95 ± 3.15 | 22.85 ± 3.56 | 0.040 |
Δneoadjuvant | − 0.79 ± 0.67 | − 0.98 ± 0.66 | − 0.45 ± 0.55 | 0.003 | − 1.11 ± 0.62 | − 0.51 ± 0.59 | 0.000 | − 1.02 ± 0.66 | − 0.62 ± 0.64 | 0.021 |
Gender, n(%) | ||||||||||
Male | 38 (66.67%) | 13 (65.00%) | 25 (67.57%) | 0.844 | 20 (66.67%) | 18 (66.67%) | 1.000 | 16 (64.00%) | 22 (68.75%) | 0.706 |
Female | 19 (33.33%) | 7 (35.00%) | 12 (32.43%) | 10 (33.33%) | 9 (33.33%) | 9 (36.00%) | 10 (31.25%) | |||
Hemoglobin (g/L), mean ± SD | ||||||||||
Pre-neoadjuvant | 118.86 ± 14.95 | 117.02 ± 15.24 | 122.26 ± 14.15 | 0.210 | 115.83 ± 14.00 | 121.59 ± 15.48 | 0.148 | 115.80 ± 16.03 | 122.77 ± 12.72 | 0.081 |
Post-neoadjuvant | 116.58 ± 13.32 | 114.89 ± 12.75 | 119.70 ± 14.10 | 0.196 | 112.75 ± 12.41 | 120.03 ± 13.36 | 0.038 | 112.01 ± 13.70 | 121.32 ± 12.32 | 0.320 |
Δneoadjuvant | − 2.27 ± 6.13 | − 2.56 ± 4.13 | − 2.13 ± 7.02 | 0.805 | − 3.08 ± 5.09 | − 1.56 ± 6.94 | 0.355 | − 3.12 ± 4.13 | − 0.79 ± 7.02 | 0.036 |
Albumin (g/L), mean ± SD | ||||||||||
Pre-neoadjuvant | 40.27 ± 3.42 | 37.95 ± 3.54 | 41.52 ± 2.64 | 0.000 | 39.08 ± 3.67 | 41.59 ± 2.59 | 0.005 | 39.14 ± 4.15 | 41.16 ± 2.44 | 0.026 |
Post-neoadjuvant | 38.57 ± 3.01 | 35.05 ± 2.95 | 40.39 ± 2.74 | 0.004 | 37.46 ± 2.74 | 39.80 ± 2.86 | 0.003 | 38.21 ± 3.82 | 40.84 ± 2.22 | 0.432 |
Δneoadjuvant | − 1.70 ± 2.57 | − 2.14 ± 2.37 | − 1.24 ± 2.17 | 0.012 | − 1.62 ± 2.66 | − 1.79 ± 2.50 | 0.806 | − 0.93 ± 3.33 | − 0.33 ± 1.03 | 0.043 |
Tumor site, n (%) | ||||||||||
Stomach | 49 (86.00%) | 18 (90.00%) | 31 (83.78%) | 0.519 | 28 (93.33%) | 21 (77.78%) | 0.091 | 21 (84.00%) | 28 (87.50%) | 0.706 |
Non-stomach | 8 (14.00%) | 2 (10.00%) | 6 (16.22%) | 2 (6.67%) | 6 (22.22%) | 4 (16.00%) | 4 (12.50%) | |||
Tumor size (cm), mean ± SD | 11.45 ± 4.41 | 11.29 ± 3.16 | 11.54 ± 5.00 | 0.838 | 11.12 ± 3.56 | 11.81 ± 5.24 | 0.557 | 11.33 ± 3.70 | 11.54 ± 4.95 | 0.861 |